Posts by: Joana Carvalho

Joana Carvalho

April 18, 2019April 18, 2019

EMA Reviewing Safety Data for Lemtrada After Reports of Serious Treatment Side Effects

News

The European Medicines Agency (EMA) is reviewing safety data for Sanofi Genzyme‘s Lemtrada (alemtuzumab) following new reports of serious treatment side effects. Lemtrada is a humanized monoclonal antibody used to slow ... Read more

April 17, 2019April 17, 2019

National MS Society Grants $24.4M to Fund 64 MS Research Projects

News

The National Multiple Sclerosis Society has granted $24.4 million to fund 64 multiple sclerosis (MS) research projects and training fellowships worldwide. This is the latest funding initiative by the Society, ... Read more

April 2, 2019April 2, 2019

NeurologyLive Launches Series of Educational Videos About MS

News

NeurologyLive has launched a series of educational videos intended to provide an overview of the diagnositic methods and treatment options available to multiple sclerosis (MS) patients. The video series, “Advances in the ... Read more

April 1, 2019April 18, 2019

FDA Approves EMD Serono’s Mavenclad as Treatment for RRMS and Active SPMS

News

The U.S. Food and Drug Administration has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS (RRMS) and active secondary ... Read more

March 26, 2019March 26, 2019

T20K in Good Position to Become Preventive MS Treatment, Cyxone Says

News

T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is ... Read more

February 27, 2019March 5, 2019

Low Socioeconomic, Education Levels Linked to Higher Disability and Disease Progression in MS, Study Says

News

Low income and education levels are linked to a higher risk of physical disability and disease progression in patients with multiple sclerosis, study says. “This study is the first of ... Read more

February 21, 2019February 21, 2019

In Creating ‘Immune Cell Atlas of Brain,’ Scientists Find Microglia Highly Complex in Behavior and Role

News

In mapping the immune system of the brain in mice and humans, scientists in Germany found that microglia — a type of nerve cell located in the central nervous system ... Read more

January 16, 2019January 16, 2019

Mindfulness Protects Against Depression, Anxiety, Fatigue, and Sleep Issues in MS Patients, Study Finds

News

Mindfulness protects against depression, anxiety, fatigue, and sleep problems in patients with multiple sclerosis (MS), improving their quality of life and overall well-being, a study finds. The study, “Longitudinal ... Read more

December 17, 2018December 17, 2018

Each Major Risk Factor (Like Genes, Smoking and Obesity) Can Affect Disease Course, Study Finds

News

Risk factors often associated with multiple sclerosis (MS), such as genetic background, obesity and smoking, contribute independently to the disease’s variability and may be an early influence on progression, ... Read more

November 14, 2018November 20, 2018

Phase 3 Trial of MD1003 in Treating Progressive MS Fully Enrolled, MedDay Announces

News

A Phase 3 clinical trial intending to confirm the potential of MD1003, a high-dose biotin, in treating progressive multiple sclerosis (MS) patients is completely enrolled, MedDay Pharmaceuticals, the investigational therapy’s developer, ... Read more

October 25, 2018October 25, 2018

PRIMERS Framework Aims to Better Understand How Exercise Helps Movement and Cognition in MS Patients

News

A new conceptual framework, called PRIMERS, has been proposed as a way of better understanding how physical exercise works to improve cognition and mobility in people with multiple sclerosis, and using what’s ... Read more

October 9, 2018October 9, 2018

Pregnancy Rates Rise Among Women with MS Over Past Decade in US, Study Shows

News

In recent years, pregnancy rates have increased among women with multiple sclerosis (MS) in the United States, according to a retrospective study, but the rate of pregnancy complications is ... Read more

August 28, 2018September 3, 2018

Exercise Fights Fatigue and Depression in MS Patients, Study Reveals

News

Physical exercise fights fatigue and depression in patients with multiple sclerosis (MS), a new study reveals. Remarkably, these positive outcomes in psychological health can be achieved without significant alterations in ... Read more

August 27, 2018August 27, 2018

Small Vesicles Involved in MS Seen to Be Affected by Gilenya, Suggesting Potential as Biomarker

News

Gilenya (fingolimod) influences the release and function of small membrane particles, called extracellular vesicles, that are involved in the development of multiple sclerosis — and these vesicles may serve a ... Read more

August 14, 2018August 14, 2018

Botox Increases Activity of Brain Regions Involved in Urinary Sensation, New Study Shows

News

Botox injections in the bladder muscle increase the activity of brain regions involved in the sensation of urinary urgency in female multiple sclerosis (MS) patients who have neurogenic overactive bladder ... Read more

August 7, 2018August 14, 2018

Vitamin D3 Insufficiency Increases MS Susceptibility in a Gene and Sex-dependent Manner

News

Vitamin D3 insufficiency increases multiple sclerosis (MS) susceptibility in a gene and sex-dependent manner, a mouse study suggests. The study with that finding, “Sex-Specific Gene-by-Vitamin D Interactions Regulate Susceptibility to ... Read more

July 31, 2018August 3, 2018

Researchers Succeed at Generating Oligodendrocytes, Key to Myelin Renewal, in Tissue Created in Lab

News

Researchers at Case Western Reserve University School of Medicine have developed a cutting-edge laboratory technique able to turn human stem cells – special cells able to grow into any type of cell ... Read more

July 27, 2018July 31, 2018

Cladribine Added to Interferon-beta Seen to Lower Relapses in Active MS, But Safety Questioned

News

Cladribine tablets added to interferon-beta treatment significantly reduced the probability of relapses over 96 weeks in people with active relapsing multiple sclerosis , a Phase 2 clinical trial found. ... Read more